Rahul Sasane
Overview
Explore the profile of Rahul Sasane including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
687
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Johnsrud M, Richards K, Arcona S, Sasane R, Leoni M
Clin Park Relat Disord
. 2021 Oct;
5:100109.
PMID: 34693271
Introduction: Most Parkinson's disease (PD) medication adherence studies have focused on patients with commercial or Medicare health insurance coverage. However, less is known regarding medication treatment patterns within the Medicaid...
12.
Sasane R, Bartels A, Field M, Sierra M, Duvvuri S, Gray D, et al.
J Clin Invest
. 2021 Apr;
131(11).
PMID: 33822767
BACKGROUNDRecently the α1 adrenergic receptor antagonist terazosin was shown to activate PGK1, a possible target for the mitochondrial deficits in Parkinson disease related to its function as the initial enzyme...
13.
Brown C, Richards K, Vohra Y, Kanu C, Stevens L, Sasane R, et al.
J Med Econ
. 2020 Dec;
24(1):38-45.
PMID: 33317379
Aims: System-level efforts have been deployed to improve oncology care and access while reducing utilization and costs. Understanding the nature of access to care from the perspective of patients themselves...
14.
Frois C, Howe A, Jarvis J, Grice K, Wong K, Zacker C, et al.
J Manag Care Spec Pharm
. 2019 Jan;
25(2):246-259.
PMID: 30698093
Background: The U.S. health care system's transition to a value-based reimbursement model holds important implications for medical innovation, care delivery, and value-based assessments of therapeutic interventions. This transition has been...
15.
Thach A, Brown C, Herrera V, Sasane R, Barner J, Ford K, et al.
Int J MS Care
. 2018 Dec;
20(6):251-259.
PMID: 30568562
Background: Adherence to disease-modifying therapy (DMT) remains problematic for many patients with multiple sclerosis (MS). An improved understanding of factors affecting DMT adherence may inform effective interventions. This study examined...
16.
Nazareth T, Ko J, Sasane R, Frois C, Carpenter S, Demean S, et al.
J Manag Care Spec Pharm
. 2017 Sep;
23(10):1018-1026.
PMID: 28944734
Background: Outcomes-based contracts (OBCs), a type of risk-sharing arrangement (RSA), have emerged as a promising avenue for payers to engage with pharmaceutical manufacturers to share risk and improve patient access...
17.
Lowe M, Blaser D, Cone L, Arcona S, Ko J, Sasane R, et al.
Value Health
. 2016 Oct;
19(6):869-878.
PMID: 27712716
Background: To ensure the creation of treatments that maximize value at the lowest cost, all aspects of the health care system need to align with patient needs and preferences. Despite...
18.
Nazareth T, Friedman H, Navaratnam P, Herriott D, Ko J, Barr P, et al.
BMC Neurol
. 2016 Sep;
16(1):187.
PMID: 27683214
Background: In the US, the approved multiple sclerosis (MS) oral disease-modifying therapies (ODMTs) are fingolimod (FTY), teriflunomide (TFN), and dimethyl fumarate (DMF). FTY and TFN are recommended with once-daily doses...
19.
Wicks P, Rasouliyan L, Katic B, Nafees B, Flood E, Sasane R
BMC Res Notes
. 2016 Sep;
9(1):434.
PMID: 27604188
Background: Oral disease-modifying therapies offer equivalent or superior efficacy and greater convenience versus injectable options. Objectives: To compare patient-reported experiences of fingolimod and dimethyl fumarate. Methods: Adult relapsing-remitting multiple sclerosis...
20.
Hodgkins P, Lloyd A, Erder M, Setyawan J, Weiss M, Sasane R, et al.
CNS Spectr
. 2016 Aug;
22(1):31-40.
PMID: 27535815
Objective: Defining minimal important difference (MID) is critical to interpreting patient-reported outcomes data and treatment efficacy in clinical trials. This study estimates the MID for the Weiss Functional Impairment Rating...